Studying a very low calorie keto diet for fatty liver disease with scarring
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with NASH and some liver scarring in the last 6 months.
- Your weight has been steady for at least 6 months and your body mass index (BMI) is between 30 and 40.
- You are willing to have a liver biopsy at the start and after 12 months to check the diet's effect.
- You do not have cirrhosis (advanced liver scarring) or other serious liver diseases.
- You do not have type 1 diabetes, and your blood tests (like liver enzymes and kidney function) are within safe limits.
- You have not had recent weight loss surgery, a liver transplant, or taken certain medications that affect the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study is for people with NASH and moderate-to-advanced liver scarring (fibrosis). Researchers want to see if they can better measure how the scarring changes over time using a liver biopsy.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study follows adults with nonalcohol-related fatty liver disease (NAFLD) to better understand the condition and what factors affect it. It may help researchers learn which patients are most at risk and how care can be improved in the future.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.